BAX Baxter International

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: diversified healthcare products including IV solutions, infusion systems, parenteral nutrition, surgical and respiratory devices
• • New segment structure: three reportable segments as of Q3 2023 — Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals
• • Strategic shift: completed sale of Kidney Care business for $3.71B net proceeds and BioPharma Solutions for $3.96B, focusing on streamlined operations
• • Debt reduction: repaid $3.81B legacy debt primarily from Kidney Care sale and additional repayments using BioPharma sale proceeds
• • Geographic footprint: products manufactured in 20+ countries and sold in 100+ countries, reinforcing global healthcare access

Risk Factors

• • FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations
• • Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified
• • Supply chain disruptions including manufacturing, sterilization, and distribution difficulties causing product availability risks
• • Competition risk from technology advances and changing consumer preferences potentially impairing new product monetization
• • Significant indebtedness requiring substantial cash flow allocation for debt service, limiting growth strategy and R&D investments

Management Discussion & Analysis

• • Kidney Care business sold for $3.80B cash, net after-tax proceeds approx. $3.3B completed Jan 31, 2025
• • Legacy indebtedness of $3.81B repaid in 2025, excluding $2.00B repaid from new notes offering
• • Kidney Care segment results reported as discontinued operations, prior periods restated accordingly
• • Cost restructuring initiated due to dis-synergies from reduced company size post-sale
• • No explicit revenue, profitability, or forward guidance disclosed in provided text

What are the latest BAX SEC filings in 2026?

Baxter International (BAX) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BAX file its most recent 10-K annual report?

Baxter International (BAX) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BAX 10-Q quarterly reports?

Baxter International (BAX)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every BAX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BAX filed recently?

Baxter International (BAX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BAX insider trading activity (Form 4)?

SignalX aggregates every BAX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BAX file with the SEC?

Baxter International (BAX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BAX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Baxter International (BAX).

What is BAX's SEC CIK number?

Baxter International (BAX)'s SEC CIK (Central Index Key) number is 10456. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 10456 to look up all BAX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BAX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Baxter International (BAX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.